December 18, 2017
Press releases
Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis
December 15, 2017
Press releases
Sanofi: FDA lifts clinical hold on fitusiran
December 13, 2017
Press releases
Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma
December 11, 2017
Press releases
FDA Approves Sanofi's Admelog® (insulin lispro injection)
December 4, 2017
Press releases
Sanofi's Toujeo® met main objective in head-to-head study versus insulin degludec
December 1, 2017
Press releases
Sanofi ends development of Clostridium difficile vaccine
November 30, 2017
Press releases
Elias Zerhouni, President of Sanofi R&D, wins 'Executive of the Year' at annual Scrip Awards
November 29, 2017
Press releases
Sanofi updates information on dengue vaccine
November 9, 2017
Press releases
Sanofi, Principia agree to develop multiple sclerosis drug candidate
November 2, 2017
Press releases
Sanofi and Alnylam present positive complete results from APOLLO Phase 3 study of investigational patisiran in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy
November 2, 2017
Press releases
Sanofi : Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed
October 24, 2017
Press releases
Sanofi Files Suit in the U.S. to Defend Its Patent Rights on Lantus® and Lantus® SoloStar®
October 16, 2017
Press releases
Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
October 12, 2017
Press releases
Sanofi invests €170 million in new vaccine production facility in France
October 11, 2017
Press releases
Sanofi: Availability of the Pre-quarterly Results Communication
October 2, 2017
Press releases
Sanofi Appoints Stefan Oelrich Executive Vice President Diabetes & Cardiovascular
September 28, 2017
Press releases
Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
September 20, 2017
Press releases
Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
September 16, 2017
Press releases
Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
September 11, 2017
Press releases
Sanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma Trial
September 8, 2017
Press releases
Sanofi, Regeneron: Cemiplimab Receives FDA Breakthrough Designation for Advanced Cutaneous Squamous Cell Carcinoma
September 7, 2017
Press releases
Sanofi rated AA by Scope Ratings
August 28, 2017
Press releases
Sanofi completes the acquisition of Protein Sciences
August 8, 2017
Press releases
Sanofi Files Suit in the U.S. to Defend its Patent Rights on Lantus®
July 31, 2017
Press releases
Sanofi: Online Availability of Sanofi Group's Half-Year Financial Report for 2017
July 31, 2017
Press releases
Sanofi Raises FY 2017 Business EPS(1) Guidance to Broadly Stable at CER(2)
July 21, 2017
Press releases
Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
July 18, 2017
Press releases
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...
July 12, 2017
Press releases
Sanofi: Availability of the Pre-quarterly Results Communication
July 11, 2017
Press releases
Sanofi to acquire Protein Sciences
July 10, 2017
Press releases
Sanofi Genzyme and Alnylam Report Positive Results from Ongoing phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or...
June 27, 2017
Press releases
Sanofi and Regeneron Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union
June 15, 2017
Press releases
Sanofi Launches "Action 2017", a Worldwide Employee Stock Purchase Plan
June 14, 2017
Press releases
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...
June 11, 2017
Press releases
Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
May 22, 2017
Press releases
Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
May 19, 2017
Press releases
Sanofi Receives CHMP Recommendation for Approval of Insulin Lispro Biosimilar
May 10, 2017
Press releases
Sanofi: Annual General Shareholders' Meeting of May 10, 2017
April 28, 2017
Press releases
Sanofi Delivers Robust Q1 2017 Financial Results
April 28, 2017
Press releases
Sanofi and Regeneron Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by US FDA
April 24, 2017
Press releases
Sanofi and Regeneron Receive CHMP Positive Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
April 14, 2017
Press releases
Sanofi: Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the...
April 11, 2017
Press releases
Sanofi: Availability of the Pre-quarterly Results Communication
April 5, 2017
Press releases
Sanofi Appoints Bill Sibold Executive Vice President Sanofi Genzyme and Member of the Executive Committee
March 28, 2017
Press releases
Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
March 4, 2017
Press releases
Sanofi and Regeneron Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of Dupixent® (dupilumab) in Moderate-to-Severe Atopic Dermatitis
March 3, 2017
Press releases
Sanofi: Filing of the 2016 U.S. Form 20-F and French "Document de Référence" containing the Annual Financial Report
March 3, 2017
Press releases
Sanofi Pasteur and MedImmune Collaborate on Monoclonal Antibody to Prevent Illnesses Associated with RSV
March 2, 2017
Press releases
Sanofi : Sanofi's Board of Directors Proposes Appointment of Melanie Lee, PhD and Bernard Charlès as New Independent Directors
February 27, 2017
Press releases
Sanofi and Lonza Enter into a Strategic Partnership to Establish a Large-Scale Biologics Production Facility
February 8, 2017
Press releases
Sanofi: Appeals Court Grants Stay of Permanent Injunction for Praluent® (alirocumab) During Appeals Process
February 8, 2017
Press releases
Sanofi Delivers 2016 Sales and Business EPS(1) Growth at CER(2)
February 1, 2017
Press releases
Sanofi's Xyzal® Allergy 24HR Approved for Over-the-Counter Use in the United States
February 1, 2017
Press releases
Sanofi and Regeneron Announce First Approval of Kevzara(TM) (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients by Health Canada
January 30, 2017
Press releases
Sanofi Appoints Kathleen Tregoning to Executive Committee and Executive Vice President, External Affairs
January 23, 2017
Press releases
Sanofi: Availability of the Pre-quarterly Results Communication
January 17, 2017
Press releases
Sanofi: SuliquaTM Approved in the European Union for the Treatment of Adults with Type 2 Diabetes
January 6, 2017
Press releases
Sanofi and Regeneron to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection
January 4, 2017
Press releases
Sanofi Announces Soliqua(TM) 100/33 Now Available in the U.S.
January 2, 2017
Press releases
Sanofi Pasteur and MSD end joint vaccines business in Europe
January 2, 2017
Press releases
Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017